SG11202111120VA - Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations - Google Patents

Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Info

Publication number
SG11202111120VA
SG11202111120VA SG11202111120VA SG11202111120VA SG11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA
Authority
SG
Singapore
Prior art keywords
tyrosine kinase
kinase inhibitor
against cancer
compounds against
egfr mutations
Prior art date
Application number
SG11202111120VA
Inventor
Jacqulyne Robichaux
Monique Nilsson
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202111120VA publication Critical patent/SG11202111120VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111120VA 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations SG11202111120VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835343P 2019-04-17 2019-04-17
PCT/US2020/028540 WO2020214824A1 (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Publications (1)

Publication Number Publication Date
SG11202111120VA true SG11202111120VA (en) 2021-11-29

Family

ID=72837936

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111120VA SG11202111120VA (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Country Status (12)

Country Link
US (1) US20220175779A1 (en)
EP (1) EP3956035A4 (en)
JP (1) JP2022529945A (en)
KR (1) KR20220004089A (en)
CN (1) CN113993592A (en)
AU (1) AU2020257395A1 (en)
BR (1) BR112021020601A2 (en)
CA (1) CA3132819A1 (en)
IL (1) IL287115A (en)
MX (1) MX2021012705A (en)
SG (1) SG11202111120VA (en)
WO (1) WO2020214824A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
JOP20210304A1 (en) 2019-05-14 2023-01-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458064A1 (en) * 2016-05-18 2019-03-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
KR102585006B1 (en) * 2016-11-17 2023-10-05 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Compounds with antitumor activity against cancer cells with EGFR or HER2 exon 20 mutations
US20180333415A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
SG11202009498RA (en) * 2018-03-27 2020-10-29 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2020005932A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
AU2019338185A1 (en) * 2018-09-04 2021-04-22 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
CA3132834A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Also Published As

Publication number Publication date
MX2021012705A (en) 2021-11-12
IL287115A (en) 2021-12-01
CN113993592A (en) 2022-01-28
EP3956035A1 (en) 2022-02-23
JP2022529945A (en) 2022-06-27
BR112021020601A2 (en) 2021-12-07
CA3132819A1 (en) 2020-10-22
US20220175779A1 (en) 2022-06-09
WO2020214824A1 (en) 2020-10-22
EP3956035A4 (en) 2023-01-25
KR20220004089A (en) 2022-01-11
AU2020257395A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL287115A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
ZA202000395B (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
EP3648753A4 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HUE057733T2 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
GB201808476D0 (en) Biomarkers for colorectal cancer
CY1123592T1 (en) AURORA A KINASE INHIBITOR
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
IL265829B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
SG11202112523UA (en) Detection of colorectal cancer
EP3955928A4 (en) Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
IL284856A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3500257A4 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
SG11202112522TA (en) Detection of colorectal cancer
EP3852762A4 (en) Novel quinazoline egfr inhibitors
IL290561A (en) Alkynyl quinazoline compounds
EP4108666A4 (en) Multi-target tyrosine kinase inhibitor
IL288522A (en) Egfr inhibitor for the treatment of cancer
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
GB201909468D0 (en) Compounds for treating cancer
EP3930837A4 (en) Quinazolinone compounds
EP3999064A4 (en) Inhibitors of tyrosine kinase
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
IL286729A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma